Compumedics (ASX:CMP) reported record sales orders taken of AU$32.8 million for the first half of fiscal 2025, up 55% year on year, according to a Wednesday filing with the Australian bourse.
The total does not include the company's MEG brain imaging technology.
The US division drove growth as sales surged 208%, the filing said. Asian booked sales orders rose 115%, while European sales grew 10%.
The medical device maker expects reported revenue of AU$23.2 million for the first half, down 13% on the year-earlier period. Excluding MEG, first-half revenue is forecast to be 6% higher year on year.
For fiscal 2025, the company anticipates sales of more than AU$55 million, excluding MEG. It also expects earnings before interest, taxes, depreciation, and amortization of above AU$5 million.
Compumedics' shares rose almost 11% in recent Wednesday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。